Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases

ObjectiveTo investigate the value of serum protoporphyrin IX (PPIX) measurement in evaluating liver damage in patients with HBV-related chronic liver diseases. MethodsA total of 110 patients who were diagnosed with HBV-related chronic liver diseases in The First Affiliated Hospital of Xi’an Medical...

Full description

Bibliographic Details
Main Author: ZHANG Ying
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2021-05-01
Series:Linchuang Gandanbing Zazhi
Online Access:http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.05.020
id doaj-2744850ef5b547fa8642cdd39e6c9a15
record_format Article
spelling doaj-2744850ef5b547fa8642cdd39e6c9a152021-05-31T07:38:15ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562021-05-0137510751080Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseasesZHANG Ying0The Second Affiliated Hospital of Xi’an Medical UniversityObjectiveTo investigate the value of serum protoporphyrin IX (PPIX) measurement in evaluating liver damage in patients with HBV-related chronic liver diseases. MethodsA total of 110 patients who were diagnosed with HBV-related chronic liver diseases in The First Affiliated Hospital of Xi’an Medical University from October 2018 to October 2019 were enrolled as case group [chronic hepatitis B (CHB) group with 50 patients, liver cirrhosis (LC) group with 40 patients, and hepatocellular carcinoma (HCC) group with 20 patients], and 40 healthy individuals were enrolled as control group. High-performance liquid chromatography was used to measure serum PPIX. A one-way analysis of variance was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test or the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; the receiver operating characteristic (ROC) curve was plotted to analyze diagnostic value; a Spearman correlation analysis was also performed to investigate correlation. ResultsThe CHB, HC, and HCC groups had a significantly higher level of PPIX than the control group [44.29 (25.99-85.36) ng/dl, 72.73 (48.28-90.43) ng/dl, and 91.79 (68.34-121.52) ng/dl vs 15.43 (10.87-20.16) ng/dl, all P<0.05], and the patients with decompensated LC had a significant increase in the level of PPIX compared with those with compensated LC [54.50(29.14~85.65) vs 76.09(53.47~104.37),Z=-2.176, P<0.05]. PPIX had a sensitivity of >85% and a specificity of >60% in the diagnosis of CHB, LC, and HCC. The patients in the latent stage of CHB had a significantly higher level of PPIX than those in the control group (Z=-4.303, P<0.05). In the patients with LC, PPIX was moderately positively correlated with total bilirubin (TBil) (rs=0.587, P<0.05) and moderately negatively correlated with albumin (rs=-0.408, P<0.05); in the patients with HCC, PPIX was moderately positively correlated with TBil (rs=0.470, P<0.05) and moderately negatively correlated with cholinesterase (rs=-0.459, P<0.05). ConclusionElevated serum PPIX is an early event of liver damage in patients with HBV-related chronic liver diseases and can thus be used as a sensitive parameter for the early warning and assessment of liver damage. http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.05.020
collection DOAJ
language zho
format Article
sources DOAJ
author ZHANG Ying
spellingShingle ZHANG Ying
Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
Linchuang Gandanbing Zazhi
author_facet ZHANG Ying
author_sort ZHANG Ying
title Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
title_short Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
title_full Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
title_fullStr Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
title_full_unstemmed Clinical significance of serum protoporphyrin IX measurement in patients with HBV-related chronic liver diseases
title_sort clinical significance of serum protoporphyrin ix measurement in patients with hbv-related chronic liver diseases
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2021-05-01
description ObjectiveTo investigate the value of serum protoporphyrin IX (PPIX) measurement in evaluating liver damage in patients with HBV-related chronic liver diseases. MethodsA total of 110 patients who were diagnosed with HBV-related chronic liver diseases in The First Affiliated Hospital of Xi’an Medical University from October 2018 to October 2019 were enrolled as case group [chronic hepatitis B (CHB) group with 50 patients, liver cirrhosis (LC) group with 40 patients, and hepatocellular carcinoma (HCC) group with 20 patients], and 40 healthy individuals were enrolled as control group. High-performance liquid chromatography was used to measure serum PPIX. A one-way analysis of variance was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test or the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; the receiver operating characteristic (ROC) curve was plotted to analyze diagnostic value; a Spearman correlation analysis was also performed to investigate correlation. ResultsThe CHB, HC, and HCC groups had a significantly higher level of PPIX than the control group [44.29 (25.99-85.36) ng/dl, 72.73 (48.28-90.43) ng/dl, and 91.79 (68.34-121.52) ng/dl vs 15.43 (10.87-20.16) ng/dl, all P<0.05], and the patients with decompensated LC had a significant increase in the level of PPIX compared with those with compensated LC [54.50(29.14~85.65) vs 76.09(53.47~104.37),Z=-2.176, P<0.05]. PPIX had a sensitivity of >85% and a specificity of >60% in the diagnosis of CHB, LC, and HCC. The patients in the latent stage of CHB had a significantly higher level of PPIX than those in the control group (Z=-4.303, P<0.05). In the patients with LC, PPIX was moderately positively correlated with total bilirubin (TBil) (rs=0.587, P<0.05) and moderately negatively correlated with albumin (rs=-0.408, P<0.05); in the patients with HCC, PPIX was moderately positively correlated with TBil (rs=0.470, P<0.05) and moderately negatively correlated with cholinesterase (rs=-0.459, P<0.05). ConclusionElevated serum PPIX is an early event of liver damage in patients with HBV-related chronic liver diseases and can thus be used as a sensitive parameter for the early warning and assessment of liver damage.
url http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.05.020
work_keys_str_mv AT zhangying clinicalsignificanceofserumprotoporphyrinixmeasurementinpatientswithhbvrelatedchronicliverdiseases
_version_ 1721419356561211392